Bio Production CMO & CRO Market Poised for Significant Growth, Projected to Reach USD 51 Billion by 2030

Bio Production CMO & CRO Market Poised for Significant Growth, Projected to Reach USD 51 Billion by 2030

 

According to Next Move Strategy Consulting, the global Bio Production CMO & CRO Market is projected to reach USD 51 billion by 2030, growing at a CAGR of 7% from 2020 to 2030. As the pharmaceutical and biotechnology sectors continue to evolve, outsourcing critical research, development, and manufacturing activities to Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) has become a key strategy to optimize resources, enhance product quality, and accelerate time-to-market.

Download FREE Sample Report: https://www.nextmsc.com/bioproduction-cmo-and-cro-market/request-sample

What is Bio Production CMO & CRO?

CMOs and CROs are specialized service providers that support biopharmaceutical companies by offering services ranging from contract manufacturing, clinical research, testing, and development to regulatory compliance and market distribution. As biological products, including biologics and biosimilars, become more complex and expensive to develop and manufacture, pharmaceutical companies are increasingly outsourcing to these experts to maintain cost-effectiveness and efficiency.

Contract manufacturers and researchers play an essential role in the biopharmaceutical industry by providing access to state-of-the-art facilities, cutting-edge technology, and a pool of skilled professionals. This collaboration allows biopharma companies to focus on their core competencies while leaving non-core activities, such as production and research, to trusted third-party providers.

Market Drivers and Trends

Several key factors are driving the growth of the Bio Production CMO & CRO Market:

  1. Surge in Demand for Biologics and Biosimilars: The growing global demand for biologics and biosimilars, driven by their efficacy in treating complex diseases, is a major contributor to the market expansion. As large pharmaceutical companies increasingly focus on developing these high-value products, the need for specialized contract manufacturing and research services continues to rise.
  2. Advancements in Biomanufacturing Technologies: The adoption of innovative technologies such as single-use bioreactors, cell culture systems, and advanced purification techniques is enhancing the capabilities of CMOs and CROs. These technologies enable manufacturers to meet the growing demand for high-quality biologics and biosimilars, accelerating production and ensuring compliance with stringent regulatory requirements.
  3. Strategic Partnerships and Mergers: To enhance their capabilities and expand their service offerings, leading players in the CMO & CRO market are increasingly entering into partnerships and acquisitions. For instance, in April 2015, Sartorius Stedim Biotech acquired BioOutsource, a UK-based CRO, to enhance its service portfolio in biologic drug safety and quality testing. Such strategic moves are enabling companies to better cater to the growing needs of biopharmaceutical clients globally.
  4. Expansion of Manufacturing Facilities: As the demand for biological drugs continues to surge, CMOs are expanding their manufacturing footprints to meet production requirements. This includes investing in new facilities, technology upgrades, and expanding production capacities for large-scale biomanufacturing. This expansion is further propelling the growth of the CMO & CRO market.
  5. Cost-Effectiveness and Resource Optimization: Outsourcing production and research activities helps biopharmaceutical companies reduce operational costs, optimize resource allocation, and focus on their core strengths. This is particularly valuable for small- and medium-sized biotech companies that lack the extensive infrastructure required for large-scale production.

Inquiry Before Buying: https://www.nextmsc.com/bioproduction-cmo-and-cro-market/inquire-before-buying

Market Segmentation

The Bio Production CMO & CRO Market is segmented as follows:

  • By Product:
    • Biologics
    • Antisense, RNAi, & Molecular Therapy
    • Biosimilars
  • By Services:
    • Contract Manufacturing
    • Contract Research
  • By Application:
    • Oncology
    • Inflammation & Immunology
    • Cardiology
    • Neuroscience
    • Others
  • By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World (RoW)

Competitive Landscape

The competitive landscape of the Bio Production CMO & CRO Market is marked by the presence of several major players who are continuously innovating and expanding their service offerings to maintain a strong market position. Key players include:

  • Lonza: A leading player in the CMO market, offering comprehensive services for the development and manufacturing of biologics.
  • Boehringer Ingelheim: A global leader in contract manufacturing of biologics and biosimilars.
  • FUJIFILM Diosynth Biotechnologies U.S.A.: A major player specializing in biologic manufacturing services, including cell line development and protein production.
  • Samsung BioLogics: A prominent contract manufacturer of biologics with advanced biomanufacturing capabilities.
  • AbbVie Inc.: A biopharmaceutical giant with significant contract research and manufacturing operations.
  • WuXi Biologics: A leading global provider of outsourced services for biopharmaceutical companies, including biologics discovery, development, and manufacturing.

These companies are employing a variety of strategies such as mergers, acquisitions, and partnerships to expand their global footprint, improve operational efficiencies, and stay ahead of the competition in an increasingly complex and regulated biopharmaceutical landscape.

Challenges

While the Bio Production CMO & CRO Market is expected to see significant growth, several challenges remain. The complexity of biologic production, the high cost of advanced manufacturing facilities, and the need for specialized expertise can pose barriers to entry for new players. Furthermore, the increasing number of companies expanding their in-house production capabilities may slow down the outsourcing trend in certain segments.

Also, Browse Related Reports:

For more information, please contact:

Next Move Strategy Consulting

E-Mail: info@nextmsc.com

Direct: +1-217-650-7991

Website: www.nextmsc.com

Follow Us: LinkedIn | Twitter | Facebook | Instagram | YouTube

 

About Next Move Strategy Consulting:

Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to provide strategically analysed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes Next Move different from the rest is its top-quality research and the obsession of turning data into knowledge by dissecting every bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations with industry experts across a diverse range of industry sectors. The high-quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to take critical business decisions that enables them to move beyond time and have competitive edge in the industry.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicates as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that range from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

Back to blog